創薬における人工知能市場：オファリング別、用途別、治療領域別、展開別、エンドユーザー別-2030年までの世界予測

世界の創薬における人工知能市場は、2023～2030年のCAGRが27.2%で、2030年までに89億5,000万米ドルに達すると予測されています。

当レポートは、広範な2次調査と1次調査、市場シナリオの詳細な分析を経て、主要な業界促進要因・阻害要因・課題・機会の分析から構成されています。

この市場の成長は、創薬における所要時間の短縮への注目の高まり、創薬におけるAIの新興国市場の拡大、慢性疾患の有病率の上昇、創薬と市場開拓のプロセスを加速するための共同研究とパートナーシップの高まりに起因すると考えられます。AIを創薬に組み込むためのリソースの制約が、このセグメントの市場拡大の大きな障害となっています。

さらに、新興経済諸国の成長と研究開発への投資の増加は、この市場の利害関係者にとって有利な機会を生み出すと予想されます。しかし、利用可能なデータセットが限られていることは、市場成長に影響を与える大きな課題です。

目次

第1章 イントロダクション

第2章 調査手法

• 調査の前提条件
• 研究の限界

第3章 エグゼクティブ概要

第4章 市場洞察

• イントロダクション
• 促進要因
  • 創薬における所要時間短縮への注目の高まり
  • 創薬におけるAIの応用拡大
  • 慢性疾患の増加
  • 創薬・薬剤開発を加速させるための共同研究やパートナーシップの増加
• 抑制要因
  • 創薬にAIを統合するためのリソースが限られていること
• 機会
  • 新興経済国
  • 研究開発投資の増加
• 課題
  • データセットの限られた入手可能性
• COVID-19が創薬における人工知能市場に与える影響

第5章 創薬における人工知能の世界市場：オファリング別

• イントロダクション
• ソフトウェア
• サービス

第6章 創薬における人工知能の世界市場：展開別

• イントロダクション
• クラウド＆ウェブベースモード
• オンプレミスモード

第7章 創薬における人工知能の世界市場：用途別

• イントロダクション
• 対象探索とバリデーション
• リード化合物の同定
• デノボデザインと薬剤最適化
• 前臨床試験と臨床試験

第8章 創薬における人工知能の世界市場：治療領域別

• イントロダクション
• がん領域
• 神経変性疾患
• 心血管疾患
• 代謝性疾患
• その他

第9章 創薬における人工知能の世界市場：エンドユーザー別

• イントロダクション
• 製薬・バイオテクノロジー企業
• 医薬品開発業務受託機関（CRO）
• 学術・研究機関

第10章 創薬における人工知能市場：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他のラテンアメリカ
• 中東・アフリカ

第11章 競合情勢

• イントロダクション
• 主要成長戦略
• 競合ベンチマーキング
• 市場シェア分析（2022年）

第12章 企業プロファイル（事業概要、財務概要、ソリューションポートフォリオ、戦略的展開）

• Microsoft Corporation
• Exscientia plc
• NVIDIA Corporation
• Schrodinger, LLC
• Atomwise, Inc.
• BenevolentAI Limited
• Deep Genomics Incorporated
• InSilico Medicine
• Cloud Pharmaceuticals, Inc.
• Standigm Inc.

第13章 付録

LIST OF TABLES

• Table 1 Global AI in Drug Discovery Market Drivers: Impact Analysis (2024-2030)
• Table 2 Global AI in Drug Discovery Market Restraints: Impact Analysis (2024-2030)
• Table 3 Global AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 4 Global AI in Drug Discovery Software Market Size, by Country/Region, 2021-2030 (USD Million)
• Table 5 Global AI in Drug Discovery Services Market Size, by Country/Region, 2021-2030 (USD Million)
• Table 6 Global AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 7 Global AI in Drug Discovery Market Size for Cloud & Web-Based Mode, by Country/Region, 2021-2030 (USD Million)
• Table 8 Global AI in Drug Discovery Market Size for On-Premises Mode, by Country/Region, 2021-2030 (USD Million)
• Table 9 Global AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 10 Global AI in Drug Discovery Market Size for Target Discovery & validation, by Country/Region, 2021-2030 (USD Million)
• Table 11 Global AI in Drug Discovery Market Size for Lead Compound Identification, by Country/Region, 2021-2030 (USD Million)
• Table 12 Global AI in Drug Discovery Market Size for De Novo Design and Drug Optimization, by Country/Region, 2021-2030 (USD Million)
• Table 13 Global AI in Drug Discovery Market Size for Preclinical & Clinical Testing, by Country/Region, 2021-2030 (USD Million)
• Table 14 Global AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 15 Global AI in Drug Discovery Market Size for Oncology, by Country/Region, 2021-2030 (USD Million)
• Table 16 Global AI in Drug Discovery Market Size for Neurodegenerative Diseases, by Country/Region, 2021-2030 (USD Million)
• Table 17 Global AI in Drug Discovery Market Size for Cardiovascular Diseases, by Country/Region, 2021-2030 (USD Million)
• Table 18 Global AI in Drug Discovery Market Size for Metabolic Diseases, by Country/Region, 2021-2030 (USD Million)
• Table 19 Global AI in Drug Discovery Market Size for Other Therapeutic Areas, by Country/Region, 2021-2030 (USD Million)
• Table 20 Global AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 21 Global AI in Drug Discovery Market Size for Pharmaceutical & Biotechnology Companies, by Country/Region, 2021-2030 (USD Million)
• Table 22 Global AI in Drug Discovery Market Size for Contract Research Organizations (CROs), by Country/Region, 2021-2030 (USD Million)
• Table 23 Global AI in Drug Discovery Market Size for Academic & Research Institutes, by Country/Region, 2021-2030 (USD Million)
• Table 24 Global AI in Drug Discovery Market Size, by Country/Region, 2021-2030 (USD Million)
• Table 25 North America: AI in Drug Discovery Market Size, by Country, 2021-2030 (USD Million)
• Table 26 North America: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 27 North America: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 28 North America: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 29 North America: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 30 North America: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 31 U.S.: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 32 U.S.: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 33 U.S.: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 34 U.S.: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 35 U.S.: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 36 Canada.: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 37 Canada: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 38 Canada: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 39 Canada: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 40 Canada.: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 41 Europe: AI in Drug Discovery Market Size, by Country/Region, 2024-2030 (USD Million))
• Table 42 Europe: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 43 Europe: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 44 Europe: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 45 Europe: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 46 Europe: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 47 Germany: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 48 Germany: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 49 Germany: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 50 Germany: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 51 Germany: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 52 France: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 53 France: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 54 France: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 55 France: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 56 France: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 57 U.K.: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 58 U.K.: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 59 U.K.: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 60 U.K.: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 61 U.K.: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 62 Italy: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 63 Italy: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 64 Italy: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 65 Italy: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 66 Italy: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 67 Spain: AI in Drug Discovery Market Size, by Offerings, 2021-2030 (USD Million)
• Table 68 Spain: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 69 Spain: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 70 Spain: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 71 Spain: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 72 Rest of Europe: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 73 Rest of Europe: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 74 Rest of Europe: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 75 Rest of Europe: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 76 Rest of Europe: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 77 Asia-Pacific: AI in Drug Discovery Market Size, by Country/Region, 2021-2030 (USD Million)
• Table 78 Asia-Pacific: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 79 Asia-Pacific: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 80 Asia-Pacific: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 81 Asia-Pacific: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 82 Asia-Pacific: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 83 China: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 84 China: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 85 China: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 86 China: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 87 China: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 88 Japan: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 89 Japan: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 90 Japan: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 91 Japan: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 92 Japan: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 93 India: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 94 India: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 95 India: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 96 India: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 97 India: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 98 Rest of Asia Pacific: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 99 Rest of Asia Pacific: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 100 Rest of Asia Pacific: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 101 Rest of Asia Pacific: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 102 Rest of Asia Pacific: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 103 Latin America: AI in Drug Discovery Market Size, by Country/Region, 2020-2029 (USD Million)
• Table 104 Latin America: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 105 Latin America: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 106 Latin America: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 107 Latin America: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 108 Latin America: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 109 Brazil: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 110 Brazil: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 111 Brazil: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 112 Brazil: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 113 Brazil: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 114 Mexico: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 115 Mexico: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 116 Mexico: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 117 Mexico: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 118 Mexico: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 119 Rest of Latin America: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 120 Rest of Latin America: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 121 Rest of Latin America: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 122 Rest of Latin America: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 123 Rest of Latin America: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 124 Middle East & Africa: AI in Drug Discovery Market Size, by Offering, 2021-2030 (USD Million)
• Table 125 Middle East & Africa: AI in Drug Discovery Market Size, by Deployment Mode, 2021-2030 (USD Million)
• Table 126 Middle East & Africa: AI in Drug Discovery Market Size, by Therapeutic Area, 2021-2030 (USD Million)
• Table 127 Middle East & Africa: AI in Drug Discovery Market Size, by Application, 2021-2030 (USD Million)
• Table 128 Middle East & Africa: AI in Drug Discovery Market Size, by End User, 2021-2030 (USD Million)
• Table 129 Recent Developments, by Company, 2020-2022

LIST OF FIGURES

• Figure 1 Research Process
• Figure 2 Key Secondary Sources
• Figure 3 Primary Research Techniques
• Figure 4 Key Executives Interviewed
• Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
• Figure 6 Market Size Estimation
• Figure 7 Global AI in Drug Discovery Market Size, by Offering, 2024-2030 (USD Million)
• Figure 8 Global AI in Drug Discovery Market Size, by Deployment Mode, 2024-2030 (USD Million)
• Figure 9 Global AI in Drug Discovery Market Size, by Therapeutic Area, 2024-2030 (USD Million)
• Figure 10 Global AI in Drug Discovery Market Size, by Application, 2024-2030 (USD Million)
• Figure 11 Global AI in Drug Discovery Market Size, by End User, 2024-2030 (USD Million)
• Figure 12 Global AI in Drug Discovery Market, by Geography
• Figure 13 Market Dynamics: AI in Drug Discovery Market
• Figure 14 Global AI in Drug Discovery Market Size, by Offering, 2024-2030 (USD Million)
• Figure 15 Global AI in Drug Discovery Market Size, by Deployment Mode, 2024-2030 (USD Million)
• Figure 16 Global AI in Drug Discovery Market Size, by Therapeutic Area, 2024-2030 (USD Million)
• Figure 17 Global AI in Drug Discovery Market Size, by Application, 2024-2030 (USD Million)
• Figure 18 Global AI in Drug Discovery Market Size, by End User, 2024-2030 (USD Million)
• Figure 19 Global AI in Drug Discovery Market Size, by Geography, 2024-2030 (USD Million)
• Figure 20 North America: AI in Drug Discovery Market Snapshot
• Figure 21 Europe: AI in Drug Discovery Market Size Snapshot
• Figure 22 Asia-Pacific: AI in Drug Discovery Market Size Snapshot
• Figure 23 Latin America: AI in Drug Discovery Market Size Snapshot
• Figure 24 Key Growth Strategies Adopted by Leading Players, 2020-2022
• Figure 25 AI in Drug Discovery Market: Competitive Benchmarking by Offering
• Figure 26 AI in Drug Discovery Market: Competitive Benchmarking by Geography
• Figure 27 Market Share Analysis: AI in Drug Discovery Market, 2022
• Figure 28 Microsoft Corporation: Financial Overview (2021)
• Figure 29 Exscientia plc: Financial Overview (2021)
• Figure 30 NVIDIA Corporation: Financial Overview (2021)
• Figure 31 Schrodinger, LLC: Financial Overview (2021)
• Figure 32 BenevolentAI Limited: Financial Overview (2021)

Artificial Intelligence in Drug Discovery Market Size, Share, Forecast, & Trends Analysis by Offering (Software, Service), Application (Target Discovery, Testing), Therapy Area (Oncology, Cardiology), Deployment, End User-Global Forecast to 2030

The global artificial intelligence in drug discovery market is projected to reach $8.95 billion by 2030 at a CAGR of 27.2% from 2023 to 2030.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities.

The growth of this market can be attributed to the rising focus on reducing turnaround time in drug discovery, growing applications of AI in drug discovery, rising prevalence of chronic diseases, and rising collaborations & partnerships to accelerate the process of drug discovery and development. The constrained resource availability for integrating AI into drug discovery poses a significant impediment to market expansion in this sector.

Moreover, the growth of emerging economies and increased investments in research & development are anticipated to create lucrative opportunities for stakeholders in this market. However, limited availability of data sets are major challenges impacting market growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2023). The key players operating in the global artificial intelligence in drug discovery market are Microsoft Corporation (U.S.), Exscientia plc (U.K.), NVIDIA Corporation (U.S.), Schrodinger, LLC (U.S.), Atomwise, Inc. (U.S.), BenevolentAI Limited (U.K.), Deep Genomics Incorporated (Canada), InSilico Medicine (U.S.), Cloud Pharmaceuticals, Inc. (U.S.), and Standigm Inc. (South Korea).

Among all the offerings studied in this report, in 2023, the software segment is expected to account for the largest share of the AI in drug discovery market. AI in drug discovery software is used for faster, efficient, and cost-effective drug discovery and enhanced clinical trials. Thus, the growing interest of pharmaceutical companies in developing novel therapies has increased the adoption of AI in drug discovery software.

Among all the deployment modes studied in this report, the cloud-based segment is projected to register the highest CAGR over the forecast period. The demand for cloud-based and web-based platforms is growing due to the benefits of cloud-based models in terms of security, flexibility, high-capacity data storage, quick accessibility, and cost-effectiveness.

Among all the therapeutic areas studied in this report, in 2023, the oncology segment is expected to account for the largest share of the global AI in drug discovery market. Numerous collaborations between drug discovery and AI companies are bolstering the significant market share of this segment. For instance, in November 2022, The University of Texas MD Anderson Cancer Center (U.S.) and Exscientia plc (U.K.) entered a strategic collaboration to combine the drug discovery & development expertise of MD Anderson with the patient-centric artificial intelligence (AI) capabilities of Exscientia, to boost the development of novel small-molecule oncology therapies. Additionally, in November 2021, Sanofi (France) announced an equity investment of USD 180 million in Owkin (U.S.), an AI and precision medicine company, aimed at advancing its oncology pipeline.

Among all the applications studied in this report, in 2023, the lead compound identification segment is expected to account for the largest share of the global AI in drug discovery market. Identifying lead compounds is a pivotal stage in drug discovery, where crucial properties like selectivity and potency are determined before advancing to clinical studies. Integrating AI can streamline pre-clinical development timelines, optimizing resource allocation effectively. Therefore, the utilization of AI in this phase of drug discovery is pivotal, contributing significantly to the large market share of this sector.

Among all end users studied in this report, in 2023, the pharmaceutical & biopharmaceutical companies segment is expected to account for the largest share of the global AI in drug discovery market. The high prevalence of chronic and infectious diseases, high pressure on the pharmaceutical, and biotechnology companies, to bring effective therapies early to the market, and combined benefits of AI algorithms in facilitating smooth drug discovery processes are key factors contributing to the significant market share of this segment.

An in-depth analysis of the geographical scenario of the global artificial intelligence in drug discovery market provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle-East & Africa), along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the artificial intelligence in drug discovery market. In North America, in 2023, the U.S. is expected to account for the largest share of the artificial intelligence in drug discovery market. The large share of this regional market is attributed to increasing public and private investments in drug discovery, and the high adoption of AI solutions in drug discovery. The presence of key AI companies and pharmaceutical companies such as Abbott Laboratories (U.S) and Pfizer Inc. (U.S) also support the large share of this market.

Scope of the Report:

Artificial Intelligence in Drug Discovery Market Assessment-by Offering

• Software
• Services

Artificial Intelligence in Drug Discovery Market Assessment-by Deployment Mode

• On-premises
• Cloud & Web-based Mode

Artificial Intelligence in Drug Discovery Market Assessment-by Application

• Target Discovery & Validation
• Lead Compound Identification
• De Novo Design and Drug Optimization
• Preclinical & Clinical Testing

Artificial Intelligence in Drug Discovery Market Assessment-by Therapeutic Area

• Oncology
• Neurodegenerative Diseases
• Cardiovascular Diseases
• Metabolic Diseases
• Other Therapeutic Areas

Note: Other therapeutic areas include infectious diseases and rare diseases.

Artificial Intelligence in Drug Discovery Market Assessment-by End Users

• Pharmaceutical & Biopharmaceutical Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes

Artificial intelligence in Drug Discovery Market Assessment-by Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• U.K
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• Rest of Asia-Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle-East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition
• 1.2. Market Ecosystem
• 1.3. Currency
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Process
• 2.2. Data Collection & Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research
• 2.3. Market Assessment
  • 2.3.1. Market Size Estimation
    • 2.3.1.1. Bottom-up Approach
    • 2.3.1.2. Top-down Approach
    • 2.3.1.3. Growth Forecast
  • 2.3.2. Market Share Analysis
• 2.4. Assumptions for the Study
• 2.5. Limitations for the Study

3. Executive Summary

4. Market Insights

• 4.1. Introduction
• 4.2. Drivers
  • 4.2.1. Rising Focus on Reducing Turnaround Time in Drug Discovery
  • 4.2.2. Growing Applications of AI in Drug Discovery
  • 4.2.3. Rising Incidences of Chronic Diseases
  • 4.2.4. Rising Collaborations and Partnerships to Accelerate the Drug Discovery and Development
• 4.3. Restraints
  • 4.3.1. Limited Availability of Resources for Integration of AI in Drug Discovery
• 4.4. Opportunity
  • 4.4.1. Emerging Economies
  • 4.4.2. Rise in the Investments for R&D
• 4.5. Challenges
  • 4.5.1. Limited Availability of Data Setss
• 4.6. Impact of COVID-19 on the AI in Drug Discovery Market

5. Global AI in Drug Discovery Market, by Offering

• 5.1. Introduction
• 5.2. Software
• 5.3. Services

6. Global AI in Drug Discovery Market, by Deployment Mode

• 6.1. Introduction
• 6.2. Cloud & Web-based Mode
• 6.3. On-premises Mode

7. Global AI in Drug Discovery Market, by Application

• 7.1. Introduction
• 7.2. Target Discovery & Validation
• 7.3. Lead Compound Identification
• 7.4. De Novo Design & Drug Optimization
• 7.5. Preclinical & Clinical Testing

8. Global AI in Drug Discovery Market, by Therapeutic Area

• 8.1. Introduction
• 8.2. Oncology
• 8.3. Neurodegenerative Diseases
• 8.4. Cardiovascular Diseases
• 8.5. Metabolic Diseases
• 8.6. Other Therapeutic Areas

9. Global AI in Drug Discovery Market, by End User

• 9.1. Introduction
• 9.2. Pharmaceutical & Biotechnology Companies
• 9.3. Contract Research Organizations (CROs)
• 9.4. Academic & Research Institutes

10. AI in Drug Discovery Market, by Geography

• 10.1. Introduction
• 10.2. North America
  • 10.2.1. U. S.
  • 10.2.2. Canada
• 10.3. Europe
  • 10.3.1. Germany
  • 10.3.2. France
  • 10.3.3. U.K.
  • 10.3.4. Italy
  • 10.3.5. Spain
  • 10.3.6. Rest of Europe
• 10.4. Asia-Pacific
  • 10.4.1. China
  • 10.4.2. Japan
  • 10.4.3. India
  • 10.4.4. Rest of Asia-Pacific
• 10.5. Latin America
  • 10.5.1. Brazil
  • 10.5.2. Mexico
  • 10.5.3. Rest of Latin America
• 10.6. Middle East & Africa

11. Competitive Landscape

• 11.1. Introduction
• 11.2. Key Growth Strategies
• 11.3. Competitive Benchmarking
• 11.4. Market Share Analysis (2022)

12. Company Profiles (Business Overview, Financial Overview, Solutions Portfolio, and Strategic Developments)

• 12.1. Microsoft Corporation
• 12.2. Exscientia plc
• 12.3. NVIDIA Corporation
• 12.4. Schrodinger, LLC
• 12.5. Atomwise, Inc.
• 12.6. BenevolentAI Limited
• 12.7. Deep Genomics Incorporated
• 12.8. InSilico Medicine
• 12.9. Cloud Pharmaceuticals, Inc.
• 12.10. Standigm Inc.

13. Appendix

• 13.1. Questionnaire
• 13.2. Available Customization